Security National Trust Co. Trims Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Security National Trust Co. lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 19,533 shares of the medical research company’s stock after selling 390 shares during the period. Thermo Fisher Scientific comprises about 1.8% of Security National Trust Co.’s investment portfolio, making the stock its 9th biggest position. Security National Trust Co.’s holdings in Thermo Fisher Scientific were worth $5,737,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in TMO. Massey Quick Simon & CO. LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $30,000. Redhawk Wealth Advisors Inc. purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $31,000. Capital Advisors Ltd. LLC boosted its position in Thermo Fisher Scientific by 250.0% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 140 shares of the medical research company’s stock valued at $41,000 after buying an additional 100 shares during the period. MRA Associates USA LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $43,000. Finally, Focused Wealth Management Inc purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $44,000. 88.17% of the stock is currently owned by institutional investors.

Shares of NYSE:TMO traded down $5.29 on Tuesday, hitting $285.16. The company had a trading volume of 1,466,739 shares, compared to its average volume of 1,567,871. The firm’s 50-day simple moving average is $283.53 and its two-hundred day simple moving average is $278.44. Thermo Fisher Scientific Inc. has a 1 year low of $208.34 and a 1 year high of $305.45. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $118.67 billion, a price-to-earnings ratio of 25.64, a P/E/G ratio of 1.94 and a beta of 1.12.



Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The firm had revenue of $6.32 billion during the quarter, compared to analysts’ expectations of $6.31 billion. During the same period last year, the company posted $2.75 EPS. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.25 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, September 17th will be given a $0.19 dividend. The ex-dividend date of this dividend is Monday, September 16th. This represents a $0.76 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is 6.83%.

Several brokerages have weighed in on TMO. Credit Suisse Group reissued a “buy” rating and set a $310.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. Needham & Company LLC increased their price target on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Monday, July 15th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price target for the company in a research report on Wednesday, June 12th. Finally, Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, May 30th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $303.17.

In other news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total value of $14,241,500.00. Following the completion of the sale, the chief executive officer now directly owns 342,193 shares of the company’s stock, valued at approximately $97,466,832.19. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 2,271 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $298.00, for a total transaction of $676,758.00. Following the completion of the sale, the chief executive officer now directly owns 283,502 shares of the company’s stock, valued at $84,483,596. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 54,104 shares of company stock valued at $15,418,539. Corporate insiders own 0.45% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: Profit margin is different from the revenue

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.